About us

If you want to chat or are looking for the next step in your healing journey you can e-mail us at [email protected]

Because we’re an international company focused on providing the best program for reversal of autoimmunity, we have clients and employees located all around the globe, with two company office headquarters located in the United States (Michigan and Florida).

Viktoriya and Oksana LLC and their team work with their clients globally and they’ve been able to help hundreds of people from all over the globe recover their health all in the comfort of their own home. 

In our Rapid Immunocellular Repair ® reversal program, we CREATE a recovery plan for your disease, your symptoms, and the status of your organ function.
 
We have different variations of our program depending on the severity of your disease and assign SPECIFIC instructions accordingly.
 
1. If you are not reversing your symptoms in 30 days, you don’t have the right recovery plan in place and you can be eating foods that are healthy, but they have an inflammatory component.
 
Having the right recovery plan where you know EXACTLY what to do, eat, how much, and how to prepare your food, is essential to stop the disease from progressing and repair the damage that has been done.
 
2. You need to know what kind of food you need to eat and in what kind of dosages to repair the immune system. Getting one ingredient wrong can prevent you from healing.
 
3. You need to know if you have an increase in symptoms, is that a healing crisis, sensitivity or a disease flare? 
 
4. Information is not enough for more people to reverse their illness, and we need to make REAL TIME adjustments to your recovery plan based on your RESULTS and how your body is responding.
 
5. You need to know how to remain disease free for life.
 
We have reversed autoimmune symptoms and lab markers for hundreds of our clients globally WITHIN 30 days without working on their trauma, without supplements, without emotional healing and without eating organic food! 
 
With this process, we have been able to reverse autoimmune symptoms within 30 days and autoimmune markers within 40-90 days (typical results our clients get in 40 days here).
 
Hundreds of testimonials of our clients shared on social media and our clients didn’t just become better, they achieved full disease reversal and many of them no longer needed medications. 
 
What we do is a results-based that takes your nutrition to the OPTIMAL level for the fastest cellular repair and immune normalization.
 
Our program was NOT designed based on the mold of other autoimmune protocols or authors/doctors but from our understanding of the immune system and through repeated EXPERIENCE.

Our program is STEP by STEP daily guidance where we will show you EXACTLY what to do in every stage of healing to keep you making progress and moving towards your ultimate goal. 

Their program(s) and our client results cannot be achieved or done without our supervision and guidance.

Click HERE to schedule your chat.

https://www.asc-abstracts.org/auth2019/gruzdyn-oksana/ 

HONORS AND AWARDS

2006 Co-founder of the Circle K International, Wayne State University Chapter

2006-2007 Outstanding Student Service Award (Michigan Campus Compact)

2007-2008 Outstanding Student Service Award (Michigan Campus Compact)

2010 Outstanding Achievement Award (Project Volunteer, Wayne State University)

2012 7th Annual David Fromm Research Award Recipient, First Price, WSUSOM

2013 8th Annual David Fromm Research Award Recipient, Third Price, WSUSOM

2014 2016 Professional Development Scholarship, Golden Key International Honour Society

10th Annual David Fromm Research Award Recipient, First Price, WSUSOM

RESEARCH EXPERIENCE

04/2008 – 01/2009

Department of Biology, Wayne State University, MI

  • Determined the effect of ISWI1 gene deletion on MET16 transcription
    receptor: Dr. Athar Ansari

01/2011 – Present

Researcher, Department of Surgery, Wayne State University School of Medicine, MI

  • Produced and manufactured recombinant self-complementary Adeno-Associated Viral (scAAV) vector encoding (a) Pre-miR-101 (b) Pre-miR-26a (c) MAGE-A3 and NY-ESO-1 (d) Green Fluorescent Protein to be used in gene therapy for pancreatic and ovarian cancers
    Generated and produced novel triple mutant AAV-6 capsid vector
    Performed dendritic cell-based immunotherapy with Cell Penetrating Domains (CPD) and rAAV-MAGE-A3, rAAV-ESO-1 of ovarian and pancreatic cancer cells
    Determined the effect of miR-101 and miR-26a re-expression on pancreatic and ovarian cancers

Skills and Techniques

  • Gene profile analysis, statistical analysis of microarray data
  • STD-PAGE and Western Blotting
  • In-situ hybridization of tissue samples
  • In vitro cell proliferation, colony formation, cell migration, cell invasion, wound-healing, chemosensitivity, apoptosis, and drug efflux assays
  • Chromatin immunoprecipitation
  • Real-Time (quantitative) PCR, mammalian cell culture, immunohistochemistry
  • Dendritic Cell isolation and purification, flow cytometry
  • Generation, purification, quantification of Adeno-Associated Virus (AAV)
  • Dendritic Cell transduction with AAV
  • Cytotoxic T Cell Lymphocyte (CTL) generation
  • Isolation of peripheral blood mononuclear cells
  • RNA and DNA isolation, purification, transformation, transduction, transfection
  • Intraperitoneal and intravenous injection of rAAV and analysis of tumor tissue samples in murine animal models
  • Writing abstracts, manuscripts, and grant proposals

 

Oral presentations at national & international conferences and meetings:

    • Central Surgical Association, March 8th, Palm Harbor, FL 2019
    • Academic Surgical Congress, February 5th, Houston, TX 2019
    • American College of Surgeons, Boston, MA 2018: Oksana was 1 of 8 nominated authors (selected out of 500 authors)
    • Clinical Application of CAR T Cells, New York, NY 2017
    • American College of Surgeons (ACS), San Diego, CA 2017
    • Central Surgical Association (CSA), Chicago, IL 2017
    • Central Surgical Association (CSA), Montreal, Quebec 2016
    • American College of Surgeons (ACS) Washington, DC 2016
    • David Fromm Research Award, January 28th, 2016 (WON FIRST PLACE; awarded a David Fromm research scholarship)
    • American College of Surgeons (ACS), Chicago, IL 2015
    • Central Surgical Association (CSA), Chicago, IL 2015
    • Academic Surgical Congress (ASC), Las Vegas, NV 2015
    • Central Surgical Association (CSA), Indianapolis, IN 2014
    • Academic Surgical Congress (ASC), San Diego, CA 2014
    • American College of Surgeons (ACS), Washington, DC 2013
    • Academic Surgical Congress (ASC), New Orleans, LA 2013
    • David Fromm Research Day, January 2013 (Won first place and a David Fromm research scholarship)
    • American College of Surgeons (ACS), Chicago, IL 2012
    • Academic Surgical Congress (ACS), Las Vegas, NV 2012
    • Peer-Reviewed Publications:
    • Click here to see our peer-reviewed publications in scientific journals on pubmed
    • and many others.


Oksana’s second author, Book Publication on HIV research, 2011:

https://www.intechopen.com/books/recent-translational-research-in-hiv-aids/crippling-of-hiv-at-multiple-stages-with-recombinant-adeno-associated-viral-mediated-rna-interferenc

AWARDS AND ACCOMPLISHMENTS

    • 7 th Annual David Fromm Research Award Recipient, 2013
    • 8 th Annual David Fromm Research Award Recipient, 2014
    • Outstanding Achievement Award (Project Volunteer, Wayne State University), 2008
    • Outstanding Student Service Award (Michigan Campus Compact), 2009
    • Professional Development Scholarship, Golden Key International Honor Society, 2008
    • Undergraduate Tuition Scholarship for Portfolio Gold Metals and Golden Key Award Scholarships 2004

PUBLICATIONS

  1. Batchu RB, Gruzdyn OV, Kolli BK, Tavva PS, Dachepalli R, Inhibition of IL-10 in the tumor microenvironment potentiates mesothelin-chimeric antigen receptor NK-92MI-mediated killing of ovarian cancer cells. J Am Coll Surg. 2020 Oct; 231(4): E54-E55.
  2. Batchu RB, Gruzdyn OV. Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer. Surgery. 2019 Oct;166: 503–508. PMID: 31416604. 
  3. Batchu RB, Gruzdyn OV. Inhibition of IL-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro. Surgery. 2018 Mar; 163:627-632. PMID: 29336814.
  4. Batchu RB, Gruzdyn OV. Inhibition of IL-10 augments mesothelin chimeric antigen receptor T cell activity in epithelial ovarian cancer. J Am Coll Surg. 227(4):e215-e216. 2018.
  5. Batchu RB, Gruzdyn OV, Qazi AM. Pancreatic cancer cell lysis by cell penetrating peptide-MAGE-A3-induced cytotoxic T lymphocytes. JAMA Surg. 151: 1086-1088. PMID: 27851862. 2016.
  6. Batchu RB, Qazi AM, Gruzdyn OV, Kaur J, Mahmud EM. Inhibition of epithelial ovarian cancer (EOC)-induced microenvironment can restore dendritic cell (DC) activation and migration. Journal of the American College of Surgeons, Volume 221, Issue 4, Supplement 2, October 2015, Page e33, ISSN 1072-7515, http://dx.doi.org/10.1016/j.jamcollsurg.2015.08.384.
  7. Batchu RB, Gruzdyn OV, Qazi AM, Kaur J. Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of pancreatic cancer. Surgery 158: 981-87, 2015.
  8. Ramesh B. Batchu, Oksana Gruzdyn. MAGE-A3 with Cell-Penetrating Domain as an Efficient Therapeutic Cancer Vaccine. JAMA Surgery, 2014; 149:451-457. PMID: 24671426
  9. Ramesh B. Batchu, Oksana Gruzdyn. Dendritic cell based immunotherapy of cancer with cell penetrating domains. Indian Journal of Surgical Oncology, 2014; 5:3-4. PMID: 24669158
  10. Batchu RB, Gruzdyn OV. Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways. Pharmaceuticals, 2014; 7:46-57. PMID: 24451403
  11. Batchu RB, Gruzdyn OV. Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector. Vaccine, 2014; 32:938-43. PMID: 24406390
  12. R.B. Batchu, O. Gruzdyn. Negative Regulation of Mutant p53 by MicroRNA-101 (miR-101) in Pancreatic Ductal Adenocarcinoma (PDAC). Journal of Surgical Research, 2013; Volume 179, Issue 2, 341
  13. RB Batchu, AM Qazi, OV Gruzdyn. EZH2-shRNA Mediated Up-regulation of p21waf1/cip1 and its Transcriptional Enhancers with Concomitant Down-modulation of Mutant p53 in Pancreatic Ductal Adenocarcinoma. Surgery, 2013; 154:739-46. PMID: 24074410
  14. A, Qazi AM, Gruzdyn OV. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1/cip1 and by inhibiting mutant p53. Cancer Letters, 2013; 336:53-60. PMID: 23603558
  15. Aamer M Qazi, Oksana Gruzdyn. Restoration of E-Cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101. Surgery, 2012; 152:704-11. PMID: 22943841
    INVITED LECTURES/ORAL PRESENTATIONS: NATIONAL/INTERNATIONAL
  16. Inhibition of TGF-β in the tumor microenvironment potentiates MSLN-CA NK-92MI-mediated killing of pancreatic cancer cells. Pittsburgh, PA, 2020 (Canceled due to COVID-19), April 2020
  17. Inhibition of IL-10 in the tumor microenvironment potentiates MSLN-CAR NK-92MI-mediated killing of pancreatic cancer cells. Central Surgical Association (CSA), virtual meeting, Milwaukee, WI, 2020 (Virtual meeting), June 2020
  18. Engineering IL-2 secreting MSLN-CAR NK-92 cell line can resist inhibition by pancreatic tumor microenvironment. Presenter, Gruzdyn, OV. Mentor, Batchu RB. Seattle, WA, April 2019
  19. Engraftment of MSLN-CAR using a hybrid sleeping beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer. National Research Week. Presenter, Gruzdyn, OV. Mentor, Batchu RB, April 2019
  20. MSLN-CAR with sleeping beauty and minicircle DNA engrafted NK-92MI cells for the treatment pancreatic cancer, CSA. Presenter, Gruzdyn, OV. Mentor, Batchu RB. Palm Harbor, FL., March 2019
  21. Sleeping beauty and minicircle design of MSLN-CAR enhances cytotoxicity in pancreatic cancer. Academic Surgical Congress (ASC). Presenter, Gruzdyn, OV. Mentor, Batchu RB. Houston, TX. , February 2019
  22. Inhibition of IL-10 can restore mesothelin chimeric antigen receptor (CAR) T cell activity in ovarian cancer. One of the 8 e-Posters of Exceptional Merit (ePOEM) presentation out of 500 abstracts, ACS, Clinical Congress. Presenter, Gruzdyn, OV. Mentor, Batchu RB. Boston, MA., October 2018
  23. MSLN-CAR-Mediated Therapy for Ovarian Cancer, ACS, Clinical Congress. Presenter, Gruzdyn, OV. Mentor, Batchu RB. San Diego, CA. , October 2017
  24. CAR-mediated therapy for pancreatic cancer. Podium Presenter: Gruzdyn OV, Mentor: Batchu RB., August 2017
  25. Efficient Lysis of Pancreatic Cancer Cells by MAGE-A3-Induced Cytotoxic T Lymphocytes (CTLs) using Cell-Penetrating Peptides (CPPs). Oral Presentation, 40th Annual Meeting, Virginia Beach, April 10-12, 2016
  26. Pancreatic Cancer-induced Microenvironment Inhibits Dendritic Cell Activation via Decreased Nuclear Localization of NF-kB. Oral Presentation, Central Surgical Association annual meeting (CSA), Montreal, QC, March 10-12, 2016
  27. Inhibition of Epithelial Ovarian Cancer (EOC)-Induced Microenvironment can Restore Dendritic Cell (DC) Activation and Migration. Oral Presentation, American College of Surgeons (ACS) Clinical Congress, Chicago, IL, October, 2015
  28. IL-10 and TGF-B Blockade Reverses the Inhibitory Effects of Pancreatic Carcinoma on Dendritic Cell Activation and Migration. Oral Presentation, 39th Annual Meeting, Miami, FL, May 2-5, 2015
  29. Enhanced Ser9 phosphorylation of p53 by miR-26a leading to growth inhibition of Pancreatic Ductal Adenocarcinoma. Oral Presentation, Central Surgical Association annual meeting (CSA), Chicago, IL, March 5-7, 2015
  30. Enhanced Chemosensitivity of Ovarian Cancer Cells via EZH1 Knockdown and Down-regulation of mTOR. Oral Presentation, 10th Annual Academic Surgical Congress (ASC), Las Vegas, NV, February 5, 2015
  31. MicroRNA-101 (miR-101) down-regulates mutant p53 in Epithelial Ovarian Cancer (EOC). Oral Presentation, 38th Annual Meeting, New Haven, CT, April, 6, 2014
  32. Enforced Expression of microRNA-26a via Adeno-Associated Viral transduction inhibits growth of Epithelial Ovarian Cancer. Oral Presentation, Central Surgical Association annual meeting (CSA), Indianapolis, IN, March 6, 2014
  33. Novel AAV-DJ Capsid Tyrosine Mutants with Enhanced Transgene Expression in a Pancreatic Cancer Cell Line. Oral Presentation, 9th Annual Academic Surgical Congress (ASC), San Diego, CA, February 4, 2014.
  34. Enhancer of Zeste Homolog 2 (EZH2) Silencing Down-modulates Mutant p53 with Increased Chemosensitivity in Epithelial Ovarian Cancer (EOC). Oral Presentation, American College of Surgeons (ACS) Clinical Congress, Washington, DC, October 7, 2013
  35. Enhanced dendritic cell permeability of genetically engineered MAGE-A3 with cell penetrating domain (CPD) for the generation of an efficient therapeutic cancer vaccine. Oral Presentation, 37th Annual Surgical Symposium, Milwaukee, WI, April, 21-23, 2013
  36. EZH2-shRNA mediated up-regulation of p21WAF1/CIP1 and its transcriptional enhancers with concomitant down-modulation of mutant p53 in pancreatic ductal adeno-carcinoma (PDAC). Central Surgical Association (CSA) Omni Amelia Island Plantation – Amelia Island, FL, March 14-16, 2013
  37. Negative Regulation Of Mutant P53 By MicroRNA-101 (miR-101) In Pancreatic Ductal Adenocarcinoma (PDAC). Oral Presentation, 8th Annual Academic Surgical Congress (ASC), New Orleans, LA, February 5, 2013
  38. Inhibition of mammalian target of rapamycin (MTOR) signaling by microrna-101 (mir-101) results in enhanced chemosensitivity of epithelial ovarian cancer (EOC) cells. 36th Annual Meeting, April 1-3, 2012
  39. Restoration Of E-Cadherin (E-Cad) Expression In Pancreatic Ductal Adenocarcinoma (PDAC) Treated With MicroRNA-101 (MiR-101). Central Surgical Association, Annual Meeting. March 1-3, Madison, Wisconsin, 2012
  40. Novel Tyrosine Mutant Recombinant Adeno-associated Viral (rAAV) Transduction of Dendritic Cells (DCs) as a Step Towards Therapeutic Vaccination in Multiple Myeloma (MM). Oral Presentation, American College of Surgeons, 98th Annual Clinical Congress, Sep 30 – Oct 4, Chicago, IL, 2012
  41. MicroRNA-101 (miR-101) Enhances Chemosensitivity Of Pancreatic Ductal Adenocarcinoma (PDAC) Cells By Inhibition Of MTOR Signaling Via PRAS40. 7th Annual Academic Surgical Congress – February 14-16, Las Vegas, NV, 2012
  42. MicroRNA-101 (miR-101) Promotes Expression Of E-cadherin (E-Cad) By Relieving Epigenetic Repression In Epithelial Ovarian Cancer (EOC). Oral Presentation, 7th Annual Academic Surgical Congress – February 14-16, Las Vegas, Nevada, 2012
    INVITED LECTURES/ORAL PRESENTATIONS: LOCAL
  43. Efficient Lysis of Pancreatic Cancer Cells by MAGE-A3-Induced Cytotoxic T Lymphocytes Using Cell-Penetrating Peptides. Oral Presentation. 10th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, April 6, 2016
  44. Pancreatic Cancer-induced Microenvironment Inhibits Dendritic Cell Activation via Decreased Nuclear Localization of NF-kB. Oral Presentation. Detroit, MI, March 25th, 2016 and again at 10th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, April 6, 2016
  45. Efficient Lysis of Epithelial Ovarian Cancer (EOC) by MAGE-A-3-Induced Cytotoxic T Lymphocytes Using rAAV-6 Capsid Mutant Vector. Oral Presentation. Detroit, MI, May 2015
  46. Enhanced Chemosensitivity of Ovarian Cancer via EZH2 Knockdown and Downregulation of mTOR. Oral presentation, 9th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, January, 2015
  47. MicroRNA-101 Down-regulates Mutant p53 in Epithelial Ovarian Cancer. 9th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, January, 2015
  48. Enhanced ser9 phosphorylation of p53 by miR-26a leading to growth inhibition of pancreatic ductal adenocarcinoma. 9th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, January, 2015
  49. rAAV-miR-101 Mediated Inhibition of EOC: Activation of p53-p21waf1/cip1 pathway. Oral Presentation, Detroit, MI, May, 2014
  50. Cell-Penetrating Domain as an Efficient Therapeutic Cancer Vaccine. Oral Presentation, 8th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI. October, 2013 (David Fromm Award Recipient)
  51. Enhancer of zeste homolog 2 (EZH2) silencing down-modulates mutant p53 with increased chemosensitivity in epithelial ovarian cancer (EOC). Oral Presentation, 8th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI. October, 2013 (David Fromm Award Recipient)
  52. Novel Tyrosine Mutant Recombinant Adeno-associated Viral Transduction of Dendritic Cells as a Step Towards Therapeutic Vaccination in Multiple Myeloma. Oral Presentation, 7th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, October, 2012 (David Fromm Award Recipient)
  53. Restoration Of E-Cadherin Expression In Pancreatic Ductal Adenocarcinoma Treated With MicroRNA-101. Oral Presentation, 6th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, October, 2011
  54. MicroRNA-101 in Cancer: Targets and Therapy. Seminars in Medicine, Medical Education Lecture Series. Detroit, MI, October, 2011.
  55. Inhibition of mTOR Signaling by MicroRNA-101 Results in Enhanced Chemosensitivity of Epithelial Ovarian Cancer Cells. 6th Annual David Fromm Research and Wayne State Surgical Alumni Day, Wayne State University School of Medicine, Detroit, MI, October, 2011
  56. Re-expressioin of microRNA-101 inhibits cell proliferation, metastasis and growth of pancreatic tumor xenografts. GI Cancer Research seminar series, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI April 29, 2011
    ABSTRACTS IN CONFERENCES
  57. IL-10 and TGF-B Blockade Reverses the Inhibitory Effects of Pancreatic Carcinoma on Dendritic Cell Activation and Migration. Oral Presentation, 39th Annual Meeting, Miami, FL, May 2-5, 2015
  58. Enhanced Ser9 Phosphorylation of P53 By miR-26a Leading to Growth Inhibition of Pancreatic Ductal Adenocarcinoma, R. B. Batchu et al. Abstract 18, 72nd Annual Meeting of the Central Surgical Association. Chicago, IL. March 5-7th, 2015
  59. Enhanced Chemosensitivity of Ovarian Cancer Cells via EZH2 Knockdown and Down-regulation of mTOR. 10th Annual Academic Surgical Congress, Las Vegas, NV, February 5, 2015
  60. Dendritic cell based immunotherapy with MAGE-A3 using Adeno-associated virus as delivery vehicle for ovarian cancer. Department of Microbiology. Rosalind Franklin University of Medicine and Science, Chicago, IL. June 3rd, 2014
  61. MicroRNA-101 (miR-101) Down-regulates Mutant p53 in Epithelial Ovarian Cancer (EOC). New Haven, CT, April 6, 2014
  62. Enforced expression of microRNA-26a via adeno-associated viral transduction inhibits growth of epithelial ovarian cancer. Central Surgical Association, Indianapolis, IN. March 6-8, 2014
  63. AAV-DJ Capsid tyrosine mutants with enhanced transgene expression in a pancreatic Cancer Cell Line. 9th Annual Academic Surgical Congress. February 4-6, San Diego, CA, 2014
  64. Enhancer of Zeste homolog 2 silencing down-modulates mutant p53 with increased chemosensitivity in epithelial ovarian cancer. Journal of American College of Surgeons. 217: S138-S139, 2013
  65. Negative Regulation of Mutant P53 by MicroRNA-101 (miR-101) in Pancreatic Ductal Adenocarcinoma (PDAC). Journal of Surgical Research. 179:341, 2013
  66. MicroRNA-101 (miR-101) Promotes Expression of E-cadherin (E-Cad) By Relieving Epigenetic Repression in Epithelial Ovarian Cancer (EOC). Journal of Surgical Research. 172: 313-314, 2012
  67. MicroRNA-101 (miR-101) Enhances Chemosensitivity of Pancreatic Ductal Adenocarcinoma (PDAC) Cells By Inhibition of MTOR Signaling Via PRAS40. Journal of Surgical Research. 172: 233, 2012
  68. Novel tyrosine mutant recombinant adeno-associated viral (rAAV) transduction of dendritic cells (DCs) as a step towards therapeutic vaccination in multiple myeloma (MM). Journal of American College of Surgeons. 215: S94, 2012
    POSTER PRESENTATIONS
  69. Pancreatic Cancer-Induced Microenvironment Inhibits Dendritic Cell Activation via Decreased Nuclear Localization of NF-κB. Detroit, MI, May, 2016
  70. Enhanced Phosphorylation of p53 by miR-26a Leading to Growth Inhibition of Pancreatic Cancer. Detroit, MI, May, 2015
  71.  MicroRNA-101 Down-regulates Mutant p53 in Epithelial Ovarian Cancer. Detroit, Michigan, May, 2014
  72.  MAGE-A3 with cell penetrating domain as an efficient therapeutic cancer vaccine. Detroit, Michigan, May, 2013
  73. Enforced expression of MicroRNA-26a via Adeno-Associated Viral transduction inhibits growth of epithelial ovarian cancer. Wayne State University School of Medicine Graduate Student Research Day, Detroit, Michigan, May, 2013
  74. Inhibition of mammalian target of rapamycin (mTOR) signaling by microRNA-101 (miR-101) results in enhanced chemosensitivity of epithelial ovarian cancer (EOC) cells. Detroit, Michigan, May 2012
  75. MicroRNA-101 (miR-101) Promotes Expression of E-cadherin (E-Cad) By Relieving Epigenetic Repression in Epithelial Ovarian Cancer (EOC). Detroit, Michigan, May 2012
  76. Novel Tyrosine Mutant Recombinant Adeno-associated Viral (rAAV) Vector Carrying MAGE-A3 Transduction of Dendritic Cells (DCs) as a Step Towards Therapeutic Vaccination in Multiple Myeloma (MM). Detroit, Michigan, May 2012
  77. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1/cip1 and by inhibiting mTOR. Detroit, MI, May 2011
  78. Re-expression of CDKN1A (p21Waf1/Cip1) by microRNA-101: Inhibition of in vitro cell proliferation, metastasis and growth of pancreatic tumor xenografts. Detroit, Michigan, May 2011

Click HERE to schedule your chat.

All rights reserved: No part of our pages/websites/images/videos may be reproduced or transmitted in any form or by any means without written permission from Viktoriya and Oksana LLC.